Avanos Medical Files 8-K with Financials
Ticker: AVNS · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1606498
| Field | Detail |
|---|---|
| Company | Avanos Medical, INC. (AVNS) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $25.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: AVNS
TL;DR
AVNS filed an 8-K on Nov 4th with financials. Nothing major, just routine updates.
AI Summary
Avanos Medical, Inc. filed an 8-K report on November 4, 2024, detailing events that occurred on November 1, 2024. The filing primarily concerns financial statements and exhibits, indicating a routine disclosure of financial information and other relevant corporate events.
Why It Matters
This filing provides updated financial information and disclosures for Avanos Medical, Inc., which is important for investors and stakeholders to assess the company's financial health and recent activities.
Risk Assessment
Risk Level: low — The filing appears to be a routine 8-K report for financial statements and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- AVANOS MEDICAL, INC. (company) — Registrant
- November 01, 2024 (date) — Date of earliest event reported
- November 4, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' for Avanos Medical, Inc.
On what date was this 8-K report filed?
This 8-K report was filed on November 4, 2024.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is November 1, 2024.
What is the company's state of incorporation?
Avanos Medical, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 5405 Windward Parkway Suite 100 South, Alpharetta, Georgia 30004.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-11-04 16:11:28
Key Financial Figures
- $0.01 — nge on which registered Common Stock - $0.01 Par Value AVNS New York Stock Exchange
- $25.0 million — which the Company may repurchase up to $25.0 million of the Company's common stock. Repurch
Filing Documents
- avns-20241101.htm (8-K) — 26KB
- avns-20241101_g1.jpg (GRAPHIC) — 15KB
- 0001606498-24-000089.txt ( ) — 191KB
- avns-20241101.xsd (EX-101.SCH) — 2KB
- avns-20241101_lab.xml (EX-101.LAB) — 23KB
- avns-20241101_pre.xml (EX-101.PRE) — 13KB
- avns-20241101_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 1, 2024, the Board of Directors of the Company approved a new one-year program under which the Company may repurchase up to $25.0 million of the Company's common stock. Repurchases under the Company's new program will be made from time to time at management's discretion on the open market or through privately negotiated transactions in compliance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act, as amended, subject to market conditions, applicable legal requirements and other relevant factors; provided, however, that the share repurchase program will not commence until at least one full trading day following the public release of any material non-public information regarding the Company. The share repurchase program does not obligate the Company to purchase any particular amount of common stock and may be suspended, modified or discontinued by the Company without prior notice.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVANOS MEDICAL, INC. Date: November 4, 2024 By: /s/ Mojirade James Mojirade James Senior Vice President and General Counsel